Literature DB >> 14735775

Assessment of anticonvulsant effectiveness and safety in patients with Angelman's syndrome using an Internet questionnaire.

Daniel H Nolt1, J Michael Mott, Wenee L Lopez.   

Abstract

An Internet questionnaire was used to collect data from caregivers about seizure activities and drug therapies of patients with Angelman's syndrome (AS). A questionnaire to collect data on AS patient demographics, seizure types, laboratory diagnosis, and past history of anticonvulsant use was developed and distributed among the membership of multiple AS groups primarily through the Internet. Caregivers of AS patients were asked to rate each drug listed on the questionnaire for its effect on the patient's behavior and alertness and on the severity and frequency of the patient's seizures. A 6-point rating scale was used, with the lowest score representing the most favorable effect. Primary considerations of the survey were to reach as many people as possible, anonymously and quickly, in a widely comprehensible format. Data were collected between March 22 and October 9, 2002. Of the 88 complete questionnaires received, 75 were electronic and 13 were handwritten responses. Forty-seven percent of respondents reported patients' use of a combination of medications at some point, with 59 different combinations described, 21 of which consisted of three or more medications. The most commonly reported regimens were valproic acid and clonazepam, valproic acid and topiramate (with or without clonazepam), valproic acid and lamotrigine, and phenytoin and carbamazepine. Patient characteristics and seizure types were consistent with those of AS patients described in the literature. Topiramate and ethosuximide were rated favorably, consistent with previously published reports. Responses to the questionnaire were widespread and rapid, with 42 responses collected in the first week. An Internet questionnaire helped collect self-reported efficacy information from caregivers of AS patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14735775     DOI: 10.1093/ajhp/60.24.2583

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  4 in total

1.  Angelman syndrome in adulthood.

Authors:  Anna M Larson; Julianna E Shinnick; Elias A Shaaya; Elizabeth A Thiele; Ronald L Thibert
Journal:  Am J Med Genet A       Date:  2014-11-26       Impact factor: 2.802

2.  Albinism and developmental delay: the need to test for 15q11-q13 deletion.

Authors:  Reem Saadeh; Emily C Lisi; Denise A S Batista; Iain McIntosh; Julie E Hoover-Fong
Journal:  Pediatr Neurol       Date:  2007-10       Impact factor: 3.372

3.  Epilepsy in Korean patients with Angelman syndrome.

Authors:  Sung-Hee Park; Jung-Rim Yoon; Heung Dong Kim; Joon Soo Lee; Young-Mock Lee; Hoon-Chul Kang
Journal:  Korean J Pediatr       Date:  2012-05-21

Review 4.  A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome.

Authors:  Jessica Duis; Mark Nespeca; Jane Summers; Lynne Bird; Karen G C B Bindels-de Heus; M J Valstar; Marie-Claire Y de Wit; C Navis; Maartje Ten Hooven-Radstaake; Bianca M van Iperen-Kolk; Susan Ernst; Melina Dendrinos; Terry Katz; Gloria Diaz-Medina; Akshat Katyayan; Srishti Nangia; Ronald Thibert; Daniel Glaze; Christopher Keary; Karine Pelc; Nicole Simon; Anjali Sadhwani; Helen Heussler; Anne Wheeler; Caroline Woeber; Margaret DeRamus; Amy Thomas; Emily Kertcher; Lauren DeValk; Kristen Kalemeris; Kara Arps; Carol Baym; Nicole Harris; John P Gorham; Brenda L Bohnsack; Reid C Chambers; Sarah Harris; Henry G Chambers; Katherine Okoniewski; Elizabeth R Jalazo; Allyson Berent; Carlos A Bacino; Charles Williams; Anne Anderson
Journal:  Mol Genet Genomic Med       Date:  2022-02-11       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.